Earnings Call Summary | ATyr Pharma(LIFE.US) Q4 2023 Earnings Conference
Earnings Call Summary | ATyr Pharma(LIFE.US) Q4 2023 Earnings Conference
The following is a summary of the ATyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript:
以下是AtyR Pharma, Inc.（LIFE）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
ATyr Pharma ended 2023 with $101.7 million in cash, restricted cash, cash equivalents, and investments.
Collaboration and license revenue related to the Kyorin agreement amounted to $0.4 million for 2023.
The company received $20 million in up-front and milestone payments from its partnership with Kyorin.
Research and development expenses were $42.3 million for the year, primarily due to clinical trial costs, Efzofitimod program manufacturing costs, and R&D costs for the Efzofitimod and discovery programs.
General and administrative expenses totalled $13 million for the year.
The company believes their current cash will be sufficient to fund the company through the filing of a biologics license application for Efzofitimod in pulmonary sarcoidosis.
截至2023年，aTyr Pharma擁有1.017億美元的現金、限制性現金、現金等價物和投資。
2023年，與Kyorin協議相關的合作和許可收入爲40萬美元。
該公司通過與Kyorin的合作獲得了2000萬美元的預付和里程碑式付款。
該年度的研發費用爲4,230萬美元，主要是臨床試驗成本、Efzofitimod項目的製造成本以及Efzofitimod和發現計劃的研發成本。
該年度的一般和管理費用共計1300萬美元。
該公司認爲，通過提交肺結節病Efzofitimod生物製劑許可證申請，他們目前的現金將足以爲公司提供資金。
Business Progress:
業務進展：
aTyr Pharma made significant progress with Efzofitimod, their leading therapeutic candidate targeted at interstitial lung disease. Multiple clinical trials are currently underway, and enrollments are expected to complete by the second quarter of this year.
The company established an expanded access program, allowing patients to continue accessing Efzofitimod post-trial.
Initial findings from their tRNA synthetases candidates in preclinical development indicate potential applications in fibrosis.
The potential global market opportunity for Efzofitimod, covering pulmonary sarcoidosis and SSc-ILD, is estimated to be around $2-$3 billion.
The company has strategies in place for potential partnerships and is exploring opportunities for maximizing their novel platform's potential.
Their current approach is disease-modifying, which could significantly outperform existing offerings.
Enrollment for a trial in Japan, as part of the strategy for global expansion, is expected to complete in Q2.
aTyr Pharma在Efzofitimod方面取得了重大進展，Efzofitimod是他們針對間質性肺病的主要候選療法。目前正在進行多項臨床試驗，註冊工作預計將於今年第二季度完成。
該公司制定了擴大准入計劃，允許患者在試驗後繼續使用Efzofitimod。
他們的tRNA合成酶候選藥物在臨床前開發中的初步發現表明了在纖維化中的潛在應用。
涵蓋肺結節病和SSC-ILD的Efzofitimod的潛在全球市場機會估計約爲20億至30億美元。
該公司已爲潛在的合作伙伴關係制定了戰略，並正在探索最大限度地發揮其新平台潛力的機會。
他們目前的方法是治療疾病，這可能會大大超過現有產品。
作爲全球擴張戰略的一部分，日本試驗的註冊預計將在第二季度完成。
More details: aTyr Pharma IR
更多詳情： aTyr Pharma
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。